Carregant...

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease

BACKGROUND: Episodic infliximab (IFX) treatment is associated with the formation of antibodies to IFX (ATIs) in the majority of patients, which can lead to infusion reactions and a shorter duration of response. Concomitant use of immunosuppressives (IS) reduces the risk of ATI formation. AIMS AND ME...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Vermeire, Severine, Noman, Maja, Van Assche, Gert, Baert, Filip, D'Haens, Geert, Rutgeerts, Paul
Format: Artigo
Idioma:Inglês
Publicat: BMJ Group 2007
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC1954977/
https://ncbi.nlm.nih.gov/pubmed/17229796
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/gut.2006.099978
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!